There is also clinical data from patients with R/R DLBCL and R/R CLL, which shows a correlation with (durable) responses and the proportion of naïve and/or memory-like CD8+ T-cells.
Hopefully, the optimised manufacturing process (which the company has talked about) for PBCAR19B has allowed them to increase the phenotype(s) without the need for a new IND application.
As for the strategies outlined in that (and other papers) for increasing efficacy will be looked at by them as they could easily be incorporated into future trials.
News 
Market Data 
Discover 
